🧬 From Prenatal Breakthroughs to Cancer’s ‘Holy Grail’: Inside BillionToOne’s Scale-Up

Key Takeaways

• One in 11 babies born in America this year will be screened by a genetic test that didn’t exist a decade ago — signaling a structural shift in prenatal diagnostics.
• BillionToOne’s core insight: detect one base-pair difference among 3 billion base pairs in the human genome by removing PCR noise with synthetic DNA controls and machine learning.
• The company is processing more than 600,000 tests a year, with close to 20% market share in its segment, and went public at a valuation of over $4 billion late last year.
• Oncology expansion is live: a cancer test launched commercially in 2023, with an ultra-sensitive MRD test for stage one patients targeted for release in less than a year.
• Capacity roadmap: current facility designed to scale to close to 2 million tests per year.

🧬 The Platform: Turning Biology into a Mathematical Problem

Conventional amplification-based genetic tests struggle to find ultra-rare variants because PCR adds noise that can bury the signal. BillionToOne’s solution is to add synthetic DNA to each patient sample before amplification, then use those known references to measure how much distortion amplification introduces across the genome. With that calibration, machine learning can subtract the noise and restore the true signal.

“There are 3 billion base pairs in the human genome… It’s usually only one base pair that’s different. So you’re looking for one base pair that’s different out of billions.”

This reframes the needle-in-a-haystack challenge: by quantifying amplification bias up front, the biology becomes a tractable counting and inference problem. That’s the namesake “billion-to-one” edge. The same method applies to both cell-free fetal DNA and cell-free tumor DNA.

📈 Commercial Traction and Scale

• Processing >600,000 tests annually with ~20% market share in prenatal screening.
• Public listing at over $4 billion valuation late last year.
• Throughput designed to scale to close to 2 million tests per year at the current facility.

Operationally, thousands of samples flow through a 5–7 day process governed by a laboratory information management system. AI and computer vision were introduced to eliminate accessioning bottlenecks with a program expressly focused on “accessioning in 60 seconds.” Liquid handling robots use optics to separate plasma (where cell-free DNA resides), and proprietary Quantitative Counting Templates (QCTs) are manufactured in-house and added to every sample to measure and correct biases.

High-density sequencing leverages sample barcoding to multiplex large cohorts:

“You actually combine all the fluids into one droplet… and then you sequence somehow a thousand patient samples all mixed together.”

After sequencing, analysis is largely automated with expert oversight. As needed, cross-functional discussions scale up — in some cases “20 people [will spend time] just discussing one sample” — while the vast majority pass the “happy path” automatically.

🚀 GTM Inflection: From One Physician to Nationwide Adoption

Early commercialization highlighted physician access as the rate-limiting step. Two months after launch, usage concentrated with one physician sending one to two tests per week. A rapid sales reset followed: an aggressive hiring mandate for five additional reps in three weeks, and a patient-first education model that generated demand back to clinicians. Inside sales spent 30–45 minutes per call educating patients, leading to about one in five kits being returned — a signal that helped recruit quality sales talent and unlock scale.

🏥 Oncology Expansion: From Late-Stage to Minimal Residual Disease

The company outlined a three-step plan as early as 2018: start with prenatal genetics, expand to late-stage cancers, and then advance to early-stage cancers. Step two is underway with a commercial oncology test launched in 2023. A case example underscores clinical leverage:

A patient in their 40s with metastatic colorectal cancer had exhausted options and was headed for hospice. BillionToOne’s blood test identified microsatellite instability in circulating tumor DNA, flagging eligibility for immunotherapy — despite prior tumor testing not showing it. The patient responded dramatically, described as the cancer “melting away,” prompting the physician to adopt blood testing broadly.

Next milestone: an ultra-sensitive MRD test for stage one patients is less than a year away. MRD detection addresses a critical gap: after curative-intent surgery for stage one–two cancers, about 20% of patients harbor microscopic residual disease undetectable by scans. The same technical breakthrough could ultimately enable population-scale screening, flagged internally as a potential “holy grail of cancer detection.”

🔧 Organization as an Edge

R&D is structured around interdisciplinary people rather than siloed teams. Small groups — a principal investigator with two or three research associates — own end-to-end product development, reporting directly to leadership for fast iteration and minimal bureaucracy. The model functions like “many startups within the company,” compounding innovation speed.

“Pressure is a privilege.”

The culture emphasizes steep challenges, rapid growth, and meaningful impact — including doing so while “being profitable.”

🧭 Strategic Context and What to Watch

• Secular adoption: With one in 11 newborns already screened by next-gen tests, non-invasive diagnostics are moving from high-risk niches to standard of care.
• Platform leverage: The same synthetic-control framework underpins prenatal, late-stage oncology, and MRD — suggesting durable cross-market economics.
• Near-term catalyst: Launch of the ultra-sensitive MRD test in less than a year.
• Capacity scaling: Expansion toward close to 2 million tests per year with current infrastructure.

Founder’s Journey: From Half a Bench to a Public Company

The company began with half a lab bench and an initial $300,000 raised over six months in $10,000 increments. Within six months of entering YC, the team built and validated its first test. Two years from idea to live commercial operations, then onward to a public listing at over $4 billion — while maintaining focus on the same founding insight: quantify amplification error, count precisely, and let computation do the heavy lifting.

Memorable Lines

“Once we are there, I think technically we would have solved the… holy grail of cancer detection.”

“We realized DNA from the fetus and the tumor is very dilute and rare… every approach requires PCR to amplify billions of fold — and that process can add tremendous noise.”

“These synthetic DNA allow us to know how much amplification happened… what errors were introduced… so we can remove those errors.”

“It converts a difficult biology problem to almost a simple mathematical problem.”

“Being resource limited is sometimes very helpful.”

---

From a prenatal breakthrough to MRD and the prospect of population-scale screening, the throughline is clear: precision counting at scale. The platform is already one of the most widely used in prenatal genetics, and the oncology roadmap pushes toward earlier, more actionable detection — potentially before cancers reach stage one.